Exemestane

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Exemestane

An FDA-approved steroidal aromatase inhibitor used to treat hormone receptor-positive breast cancer.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Exemestane (Aromasin) is a steroidal aromatase inhibitor that covalently and irreversibly binds aromatase, inactivating it. FDA approved on October 21, 1999, for advanced breast cancer in postmenopausal women after tamoxifen failure. Approved October 5, 2005, for adjuvant treatment of early breast cancer after 2-3 years of tamoxifen.

Benefits reported in the imported source

• Advanced breast cancer in postmenopausal women who have stopped responding to tamoxifen.
• Adjuvant treatment of early breast cancer.

Risks and limits

• Lipid abnormalities
• Bone loss and increased fracture risk
• Arthralgia
• Hot flashes

Source bottom line: FDA-approved steroidal aromatase inhibitor with irreversible mechanism for hormone receptor-positive breast cancer.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 24 hours. FDA label, Aromasin: mean terminal half-life about 24 hours Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• DailyMed: exemestane
• Exemestane Hormonal Therapy - LBBC
• Endocrinological Evaluation of Exemestane - PubMed Central (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)